| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10962085 | Tuberculosis | 2013 | 7 Pages |
Abstract
The clinical, regulatory and research environment for modern efficacy trials of new TB vaccines are substantially different to that when BCG vaccine was first evaluated in infants. Future infant TB vaccine trials will need to allocate sufficient resources and optimise operational efficiency. A stringent TB case definition is necessary to maximize specificity, and TB case accrual must be monitored closely.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Michele Tameris, Helen McShane, J. Bruce McClain, Bernard Landry, Stephen Lockhart, Angelique K.K. Luabeya, Hennie Geldenhuys, Jacqui Shea, Gregory Hussey, Linda van der Merwe, Marwou de Kock, Thomas Scriba, Robert Walker, Willem Hanekom, Mark Hatherill,